Glycopyrrolate inhaled - Pearl Therapeutics

Drug Profile

Glycopyrrolate inhaled - Pearl Therapeutics

Alternative Names: GP MDI; PT-001; PT001 GP

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pearl Therapeutics
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II/III Asthma

Most Recent Events

  • 13 Dec 2017 Phase-II/III clinical trials in Asthma (In adolescents, In adults, In children, In the elderly) in USA (Inhalation) (NCT03358147)
  • 30 Nov 2017 Pearl Therapeutics plans a phase II/III trial for Asthma in December 2017 , (NCT03358147)
  • 31 Aug 2017 Pearl Therapeutics completes a phase III trial in Chronic obstructive pulmonary disease in Hungary, Poland, Czech Republic, Germany, United Kingdom, USA (Inhalation) (NCT02343458) (EudraCT2014-004712-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top